We are excited to welcome the talented team at Regulus to Novartis as we continue to build on our pipeline in renal disease with high unmet medical need.” Farabursen is an investigational ...

Multiple early-stage players such as Aegle Therapeutics, ZEO ScientifiX, StemXO Therapeutics, Codiak BioSciences, Vitti Labs, Aruna Bio, EXO Biologics, EV Therapeutics, ReNeuron, Coya Therapeutics ...

OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as Chief Development Officer NANTES, France, January 13, 2025 – 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today ...

Evox raised $95.4 million in 2021; Evox Therapeutics is focused on the treatment of severe rare genetic diseases using their exosome-based therapies. Evox has developed a proprietary technology ...

OXFORD, United Kingdom, April 29, 2024 (GLOBE NEWSWIRE) -- Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, announces that Dr. Per Lundin, Co ...

OXFORD, United Kingdom, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Evox Therapeutics Ltd ('Evox'), a leading exosome therapeutics company, today announced the publication in Nature Communications of Evox ...

OXFORD, United Kingdom, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Evox Therapeutics Ltd ('Evox'), a leading exosome therapeutics company, today announced a research collaboration and option agreement with ...